PPARG and metabolic dysfunction-associated steatohepatitis: Consistent with present findings, PPAR‐γ agonists reportedly inhibit proinflammatory cytokines and oxidative stress in the liver of NASH mice (Wu et al., 2010), which may lead to improved insulin resistance, hepatic lipid metabolism, and liver injury.